Torsten Haferlach

60PUBLICATIONS
384CO-AUTHORS
Molecular targetsRegenerative medicine (incl. stem cells)Gene and molecular therapyMedical mycologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (60)

|Sep 04, 2026
Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jul 13, 2026
The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML.

|Feb 17, 2026
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

C Riedhammer, M Truger, H Lee

|Jan 14, 2026
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

Alberto Hernández-Sánchez, Ángela Villaverde Ramiro, Eric Sträng

|Dec 19, 2025
Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.

Marietta Truger, Manja Meggendorfer, Wencke Walter

Pageof 10

Frequent Collaborators

25 joint publications

Claudia Haferlach

20 joint publications

Manja Meggendorfer

19 joint publications

Wolfgang Kern

16 joint publications

Wencke Walter